Factor V leiden homozygosity, dyspnea, and reduced pulmonary function
- PMID: 16186475
- DOI: 10.1001/archinte.165.17.2032
Factor V leiden homozygosity, dyspnea, and reduced pulmonary function
Abstract
Background: Factor V Leiden homozygosity predisposes patients to deep venous thrombosis and major pulmonary thromboembolism. Consequently, factor V Leiden homozygosity could, via unrecognized repeated minor pulmonary thromboemboli, cause chronic pulmonary disease. We tested the hypothesis that factor V Leiden homozygosity is associated with pulmonary symptoms and signs.
Methods: We studied a general population sample of 9253 individuals from the Copenhagen City Heart Study who were examined in 1991-1994. Of these, 6475 participants were also examined in 1976-1978 and/or 1981-1983. End points were dyspnea and lung function.
Results: Among 20 factor V Leiden homozygotes, a mean +/- SD of 32% +/- 11% had severe dyspnea compared with 6% +/- 0.3% of 8534 noncarriers (chi(2) test; P<.001). The corresponding adjusted odds ratio for severe dyspnea was 5.4 (95% confidence interval, 1.9-15.7). During follow-up, forced expiratory volume in 1 second and forced vital capacity were 5% to 10% lower in homozygotes vs noncarriers (analysis of variance; P = .003 and P = .03). The annual mean +/- SD loss of forced expiratory volume in 1 second and forced vital capacity was 39 +/- 8 mL/y and 35 +/- 8 mL/y in homozygotes vs 21 +/- 10 mL/y and 15 +/- 10 mL/y in noncarriers (t test; P = .03 and P = .04), respectively. Factor V Leiden heterozygosity (n = 699) did not influence pulmonary symptoms and signs.
Conclusion: We demonstrate a previously unrecognized clinical presentation of factor V Leiden homozygosity with severe dyspnea and decreased pulmonary function.
Similar articles
-
Factor V Leiden and fatal pulmonary embolism.Thromb Haemost. 1998 Mar;79(3):511-6. Thromb Haemost. 1998. PMID: 9531031
-
Factor V Leiden mutation in patients with Behçet's disease.J Rheumatol. 1998 Mar;25(3):496-8. J Rheumatol. 1998. PMID: 9517770
-
Minor injuries as a risk factor for venous thrombosis.Arch Intern Med. 2008 Jan 14;168(1):21-6. doi: 10.1001/archinternmed.2007.5. Arch Intern Med. 2008. PMID: 18195191
-
The relationship between FV Leiden and pulmonary embolism.Respir Res. 2002;3(1):8. doi: 10.1186/rr180. Epub 2001 Nov 19. Respir Res. 2002. PMID: 11806843 Free PMC article. Review.
-
[Pulmonary problems related to aging].Rev Med Liege. 1997 Apr;52(4):245-50. Rev Med Liege. 1997. PMID: 9273615 Review. French. No abstract available.
Cited by
-
Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.Thromb J. 2024 Apr 4;22(1):34. doi: 10.1186/s12959-024-00599-3. Thromb J. 2024. PMID: 38576023 Free PMC article. Review.
-
Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.J Clin Med. 2021 May 11;10(10):2061. doi: 10.3390/jcm10102061. J Clin Med. 2021. PMID: 34064992 Free PMC article. Review.
-
Second-Hand Smoke Exposure Associated with Risk of Respiratory Symptoms, Asthma, and COPD in 20,421 Adults from the General Population.J Asthma Allergy. 2021 Oct 28;14:1277-1284. doi: 10.2147/JAA.S328748. eCollection 2021. J Asthma Allergy. 2021. PMID: 34737580 Free PMC article.
-
Venous thromboembolism associated with severe dyspnoea and asthma in 102 792 adults.ERJ Open Res. 2023 Nov 20;9(6):00631-2023. doi: 10.1183/23120541.00631-2023. eCollection 2023 Nov. ERJ Open Res. 2023. PMID: 38020573 Free PMC article.
-
The association between blood coagulation activity and lung function: a population-based study.PLoS One. 2010 Nov 16;5(11):e15014. doi: 10.1371/journal.pone.0015014. PLoS One. 2010. PMID: 21103357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical